DALLAS, May 21, 2019 /PRNewswire/ -- Jacobs (NYSE:
JEC) has been selected to provide construction management services
for global biologics leader, WuXi Biologics, to support the
development of its new biologics drug substance manufacturing
facility located in Dundalk, Co. Louth,
Ireland. The new facility, modelled on the "Factories of the
Future" concept, will incorporate best-in-class innovative
technology optimized for the flexible production of a wide range of
biologic drugs for customers globally.
Supported by the Irish Government through IDA Ireland, which they estimate to cost more than
$394 million, the project is expected
to accelerate the development of biologics in Europe and help increase investment and jobs
in Ireland under the Regional
Action Plans for Jobs initiative. WuXi's investment will result in
the creation of 400 highly skilled jobs over five years as well as
approximately 700 construction jobs.
"This project shows how we partner with our life sciences
clients to advance cutting-edge facilities and drug therapies,
while supporting the communities where we live and work," said
Jacobs Buildings, Infrastructure and Advanced Facilities Senior
Vice President and General Manager Ken
Gilmartin. "WuXi has given us the opportunity to deliver a
state-of-the art project to help them serve a global patient
population, while furthering the ambition to make Ireland a global center of excellence in
biologics, driving investment in Co.
Louth and creating highly skilled jobs."
The 26-hectare biomanufacturing facility, WuXi's first outside
of China, will incorporate
traditional fed-batch or perfusion process and continuous
bioprocessing, a next-generation processing technology using
selected single-use cell culture and fixed stainless-steel elements
for purification. When completed, a total capacity of 48,000L
fed-batch and 6,000L perfusion will be installed, representing one
of the world's largest plants using single-use bioreactors.
Jacobs leads the global professional services sector delivering
solutions for a more connected, sustainable world. With
approximately $12 billion in revenue
and a talent force of more than 50,000, Jacobs provides a full
spectrum of services including scientific, technical, professional
and construction- and program-management for business, industrial,
commercial, government and infrastructure sectors. For more
information, visit www.jacobs.com, and connect with Jacobs on
LinkedIn, Twitter, Facebook and Instagram.
Certain statements contained in this press release constitute
forward-looking statements as such term is defined in Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and such statements
are intended to be covered by the safe harbor provided by the same.
Statements made in this release that are not based on historical
fact are forward-looking statements. We base these forward-looking
statements on management's current estimates and expectations as
well as currently available competitive, financial and economic
data. Forward-looking statements, however, are inherently
uncertain. There are a variety of factors that could cause business
results to differ materially from our forward-looking statements.
For a description of some additional factors that may occur that
could cause actual results to differ from our forward-looking
statements see our Annual Report on Form 10-K for the year ended
September 28, 2018, and in particular
the discussions contained under Item 1 - Business; Item 1A - Risk
Factors; Item 3 - Legal Proceedings; and Item 7 - Management's
Discussion and Analysis of Financial Condition and Results of
Operations, and our Quarterly Report on Form 10-Q for the quarter
ended March 29, 2019, and in
particular the discussions contained under Part I, Item 2 -
Management's Discussion and Analysis of Financial Condition and
Results of Operations; Part II, Item 1 - Legal Proceedings; and
Part II, Item 1A - Risk Factors, as well as the Company's other
filings with the Securities and Exchange Commission. The Company is
not under any duty to update any of the forward-looking statements
after the date of this press release to conform to actual results,
except as required by applicable law.
For press/media inquiries:
Kerrie Sparks
214.583.8433
Brian Morandi
720.286.0719
View original content to download
multimedia:http://www.prnewswire.com/news-releases/jacobs-wins-contract-to-provide-construction-phase-services-for-wuxi-biologics-biomanufacturing-facility-300853704.html
SOURCE Jacobs